Together with previously observed higher numbers of maintained T-cell clones during CTLA4 inhibition (17), our data on restricted TCR repertoires support the view that pre-existing T-cell clones may be relevant for anti-tumor responses under CTLA4 blockade in melanoma patients, with a possibly greater relevance of CD4 T cells. The gene discussed is CTLA4; the disease is melanoma.